1. Home
  2. BSX vs SNY Comparison

BSX vs SNY Comparison

Compare BSX & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BSX
  • SNY
  • Stock Information
  • Founded
  • BSX 1979
  • SNY 1994
  • Country
  • BSX United States
  • SNY France
  • Employees
  • BSX N/A
  • SNY N/A
  • Industry
  • BSX Medical/Dental Instruments
  • SNY Biotechnology: Pharmaceutical Preparations
  • Sector
  • BSX Health Care
  • SNY Health Care
  • Exchange
  • BSX Nasdaq
  • SNY Nasdaq
  • Market Cap
  • BSX 138.4B
  • SNY 127.2B
  • IPO Year
  • BSX 1992
  • SNY N/A
  • Fundamental
  • Price
  • BSX $105.15
  • SNY $49.37
  • Analyst Decision
  • BSX Strong Buy
  • SNY Buy
  • Analyst Count
  • BSX 22
  • SNY 2
  • Target Price
  • BSX $111.64
  • SNY $62.50
  • AVG Volume (30 Days)
  • BSX 6.7M
  • SNY 2.4M
  • Earning Date
  • BSX 07-23-2025
  • SNY 07-24-2025
  • Dividend Yield
  • BSX N/A
  • SNY 4.48%
  • EPS Growth
  • BSX 15.23
  • SNY 39.56
  • EPS
  • BSX 1.37
  • SNY 5.45
  • Revenue
  • BSX $17,554,000,000.00
  • SNY $48,817,552,946.00
  • Revenue This Year
  • BSX $17.56
  • SNY $3.39
  • Revenue Next Year
  • BSX $10.75
  • SNY $7.05
  • P/E Ratio
  • BSX $76.80
  • SNY $17.77
  • Revenue Growth
  • BSX 19.36
  • SNY N/A
  • 52 Week Low
  • BSX $71.88
  • SNY $45.80
  • 52 Week High
  • BSX $107.17
  • SNY $60.12
  • Technical
  • Relative Strength Index (RSI)
  • BSX 57.52
  • SNY 38.24
  • Support Level
  • BSX $103.50
  • SNY $51.80
  • Resistance Level
  • BSX $106.67
  • SNY $52.41
  • Average True Range (ATR)
  • BSX 1.64
  • SNY 0.83
  • MACD
  • BSX -0.21
  • SNY -0.06
  • Stochastic Oscillator
  • BSX 63.63
  • SNY 16.44

About BSX Boston Scientific Corporation

Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.

About SNY Sanofi ADS

Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

Share on Social Networks: